

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



PATENT TRADEHARK OFFICE In re United States Patent Application of: 4115-116 DIV 4 Docket No.: Gallo et al. Applicant: Not yet assigned. Examiner: 09/677,152 Serial No.: Not yet assigned. Group Art Unit: October 2, 2000 Date Filed: 2 Paper No.: THERAPEUTIC FRACTIONS OF RECEIVED Title: SOURCES OF hCG FIRST CLASS MAIL CERTIFICATE JAN 12 200! I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed TECH CENTER 1600/2900 to the Commissioner for Patents, Washington, DC 20231, and First Class Mailed under the provisions of 37 CFR 1.8. January 3, 2001

INFORMATION DISCLOSURE STATEMENT

Date of Mailing

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449.

Documents AA to ID were previously submitted in the parent application (U.S. Patent Application No. 09/220,415); copies of such documents were previously submitted in such application.

It is respectfully requested that the information listed on the attached PTO-1449 be expressly considered during the prosecution of this application, and that the reference(s) be made of record and appear among the "References Cited" on any patent to issue therefrom.

Respectfully submitted,

Steven J. Hultquist Reg. No. 28,021 Attorney for Applicant

INTELLECTUAL PROPERTY/ TECHNOLOGY LAW

P.O. Box 14329

Research Triangle Park, NC 27709 Telephone: (919) 419-9350 Fax: (919) 419-9354 Attorney Ref: 4115-116 DIV 4



ATTORNEY DOCKET NO. 4115-116 DIV 4

SERIAL NO. 09/677,152

GROUP

APPLICANT Gallo et al. INFORMATION DISCLOSURE STATEMENT

FILING DATE October 2, 2000

(use several sneets if necessary)			FILING DATE October 2, 2000		1649		
			U.S.	PATENT DOCUMENTS			FILING DATE IF APPROPRIATE
EXAMINER		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	IF APPROPRIATE
INITIAL	AA	4,400,316	8/23/83	Katsuragi et al.			
Je	AB	4,689,222	8/25/87	McMichael			
	AC	4,691,006	9/1/87	Stevens			ECEIVED
	AD	4,692,332	9/8/87	McMichael			6 0 2001
	AE	4,713,366	12/15/87	Stevens			JAN 12 200!
	AF	4,714,680	12/22/87	Civin et al.			LECH CENTER 1800/2900
	AG	4,880,626	11/14/89	McMichael			
	AG	4,000,020	FOR	EIGN PATENT DOCUME	NTS		TRANSLATION

	 COUNTRACT	PUBLICATION	PATENT DOCUMEN	CLA	CC	SUBCLAS	1	SLATI(
	DOCUMENT NUMBER	DATE	COUNTRY	CLA		Seres		
Al	 WO 90/02759	3/22/90	PCT		1	 		
AI AI	 WO 91/09872	7/11 /91	PCT		_			_
A	 WO 92/22654	12/23/92	PCT		1			
$\frac{1}{A}$	 WO 94/20859	9/15/94	PCT					
$\frac{1}{A}$	 WO 94/24148	1	PCT					
	 06/04009	2/15/96	PCT ng Author, Title, Journ				7.	

╌╉╾╼╼╼┼	A N 4	WO 96/04008	2/15/96			
) A	AM	110 30, 31	JMENTS (Including Author, Title, Journal-D	-Date, Page Number, Etc.)		
	N	OTHER DOCL	IMENTS (Include	ding Author, Title, oduran		
1./	ANI	Abrams et al., 1	983, J. Cell. Bloc	mem. Supply		
10	AO	Aizawa and Tay	assoli, 1986, Int.	J. Cell Cloning 4:464-471		
		A drawa et el	1986, Blood 67;8	842-845		
	AP	Andrews et al.,	1700, Blood 27,	1030-1035		
=4,1	AQ	Andrews et al.,	1986, Blood 68;1	1030-1033		
-	AR	Ballem et al., 1	987, J. Clin. Inve	est. 80:33-40		
		Dollam et al 1	992. New Eng. J.	. Med 327:1779-1784		
	AS	Ballelli et al., 1	1 1002 Saint	nce 220:868-870		
	AT	Barre-Sinoussi	et al., 1983 Scien	nce 220:868-870		
	AU	Bauman et al.,	1986, J. Cell Phy	ysiol. 128:133-142		
.1	1			Continue on Page 2		
					T DATE CONSIDERED	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if chation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.


Sheet <u>2</u> of 10 SERIAL NO. ATTORNEY DOCKET NO. US Dept. of Commerce 09/677,152 4115-116 DIV 4 Patent and Trademark Office APPLICANT Gallo et al. INFORMATION DISCLOSURE STATEMENT GROUP FILING DATE (use several sheets if necessary) October 2, 2000 U.S. PATENT DOCUMENTS FILING DATE IF APPROPRIATE SUBCLASS CLASS **PATENT** NAME **EXAMINER** ISSUE DATE NUMBER INITIAL McMichael 10/30/90 4,966,753 AVBoyse et al. 4/2/91 5,004,681 AW Ivanoff et al. 8/25/92 5,141,867 AXBoyse et al. 3/9/93 5,192,553 AY Herron 1/10/95 5,380,668 AZSarin et al. 9/19/95 5,451,527 BA McMichael 3/11/97 5,610,136 BBFOREIGN PATENT DOCUMENTS TRANSLATION NO YES **SUBCLASS PUBLICATION CLASS** DOCUMENT **COUNTRY** DATE **NUMBER** EΡ 4/21/82 0 049 898 B2 BC EΡ 5/22/85 0 142 387 A1 BDBE BF BG OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) BHBellet et al., 1984, Endocrinology 115:330-336 BI Berchtold and Wenger, 1993, Blood 81:1246-1250 BJBidart et al., 1987, Mol. Immunology 24:339-345 BKBidart et al., 1987, J. Biol. Chem. 262:15483-15489 BLBidart et al., 1990, Science 248:736-739 Blazevic et al., 1995, AIDS Res. Hum. Retroviruses 11:1335-1342 BM BN Bodger, et al., 1983, Blood 61:1006-1010 BO Bolognesi, 1993, Semin. Immunol. 5:203-214 BP

BQ Bourinbaiar and Nagorny, 1992, FEMS Microbiol. Lett. 96:27-30

Continue on Page 3

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

DATE CONSIDERED



ATTORNEY DOCKET NO. US Dept. of Commerce 4115-116 DIV 4 Patent and Trademark Office

SERIAL NO. 09/677,152

APPLICANT Gallo et al.

INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)

FILING DATE October 2, 2000 GROUP

			U.S.	PATENT DOCUMENTS	1	SUBCLASS	FILING DATE IF APPROPRIATE
XAMINER		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	
INITIAL	BR	5,677,275	10/14/97	Lunardi-Iskandar et al.		-	
10		5,700,781	12/23/97	P.J. Harris		1000	
01	BS		9/22/98	A.S. Bourinbaiar	514	008	
	BT	5,811,390		Haigwood et al.	1	1	
	BU	5.614.612	3/25/97				
	BV	5,494,899	2/27/96	Kincade et al.		+	
	BW	5508,261	4/16/96	Moyle et al.			
		5,635,599	6/3/97	Pastan et al.			
	BX		8/9/88	Stevens			
	BY	4,762,913		Stevens			
	BZ	4,767,842	8/30/88				
	CA	4,855,285	8/8/89	Stevens			
	CB	4,161,519	7/17/79	Talwar			
	CC	700 212	10/25/88	Talwar			
		1					
			_	cluding Author, Title, Journ		Number 5	itc)


OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) CD | Bourinbaiar and Nagorny, 1992, FEBS Microbiol. Lett. 309:82-84

	1	Author, Title, Journal-Date, 1 ago
		OTHER DOCUMENTS (Including Author, Title, Journal-Date, 1 ago 1007 FEBS Microbiol. Lett. 309:82-84
	<u>-</u>	B. inheigrand Nagomy, 1992, 1999
15		1005 Imminol, Lett. 44.13 17
- di	CE	Bourinbalar and Bee 11 Clin Endorcrinology and Metabolism 47:326-332
	CF	Bourinbaiar and Lee-Huang, 1993, minteness Braunstein et al., 1978, J. Clin. Endorcrinology and Metabolism 47:326-332
		1004 I Clin Invest 13:937-733
}	CG	Broxmeyer et al., 1984, J. Chir Hivest. 7577 Broxmeyer, 1983, CRC Critical Reviews in Oncology/Hematology 1:227-257
	CH	Broxmeyer, 1983, CRC Critical 19
	CI	Broxmeyer, 1982, J. Clin Invest. 69:632-642
		Busch et al., 1987, Blut 54:179-188
	Cl	Busch et al., 1767, 2000
	CK	Cain at al., 1986, Transplantation 41:22-25
		Continue on Page 4
		IDATEUNSIDERE

EXAMINER

DATE CONSIDERED

EXAMINER: Initial in citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



ATTORNEY DOCKET NO. 4115-116 DIV 4

SERIAL NO. 09/677,152

INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)

APPLICANT Gallo et al. GROUP FILING DATE

NFORMALI	- avaral o	cheets if necessary)								
(use	e severai :	October 2, 2000 October 2, 2000 Number, Etc.)								
	OT	October 2, 2000 THER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)								
EXAMINER										
NITIAL	CL	Cao at al., 1982, J. Med. Genet. 19:81-87								
10		Caraux et al., 1985, J. Immun. 134:835-840								
7	CM	Caraux et al., 1983, 3. Allandar								
		Chak et al., 1988, J. Clin. Oncol. 6:863-867 Chen et al., 1992, AIDS 6;533-539								
	co									
		Clavel et al., 1986, Science, 233-343-346								
		Cocchi et al., 1995, Science, 270-1811-1815								
	CQ	Daffos, et al., 1983, am. J. Obstst. Gynecol. 146:985-987								
	CR	Daffos, et al., 1985, am. J. Obstst. Gynecol. 153:655-660								
	CS	Daffos, et al., 1983, all. J. Costst. 277								
	CT	Dalgleish et al., 1984, Nature 312: 763-767								
	CU	De at al., 1997, J. Clin. Invest. 99:1484-1491								
	CV	Delli-Bovi et al., 1986, Cancer Res. 46:6333-6338								
	CW	Deshmukh et al., 1994, J. Clin. Immunol. 14:162-168								
		Dexter et al., 1977, J. Cell. Physiol. 91:335-344								
	CX	Dickie et al, 1991, Virology, 185:109-119								
	CY	Dickie et al, 1991, Vitology, 12								
	CZ	Dirnhofer et al. 1993, FASEB J. 7:1381-1385								
	DA	Dirnhofer et al. 1994, J. Endocrinology 141:153-162								
	DB	Emerson et al., 1985, J. Clin. Invest. 76:1286-1290								
e e e e	DC	Ensoli et al., 1989, Science 243:223-226								
	DD	1000 Science 249:527-533								
		1 1001 I Immunotherapy 10:39-50								
	DE	1083 Proc Natl. Acad. Sci. USA 80:4114								
	DF	Ferrero et al., 1965, 1166 1881								
	DG	Ferrero et al., 1986, Cancer Res. 46:975-980								
	DH	Franks et al., 1995, Pediatric Res. 37:56-63								
	DI	Friedman-Kien et al., 1981, J. Am. Acad. Dermatol. 5:468-473								
	DJ	1 1084 Science 224:500-503								
		1087 Am J. Med. 82:456-462								
	Di	Continue on Page 5								
		DATE CONSIDERED								

EXAMINER EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.



Sheet <u>5</u> of 10

SERIAL NO.

09/677,152

US Dept. of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 4115-116 DIV 4
Patent and Tax	APPLICANT Gallo et al.

INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)

FILING DATE
October 2, 2000
GROUP

-		Tarmal Nate I	Page Number, Etc.)						
	OTHER DOCUMENTS	(Including Author, Title, Journal-Date, I							
XAMINER NITIAL	1 1085 Arc	hs. Path. Lab. Met. 109:138-145							
es	DL Geller et al., 1963, Ale	Orgal 13:315-319							
	DM Gill et al., 1990, Am. J	. Clin. Oncol. 13:315-319							
<u> </u>	DN Gill et al., 1991, Am.	J. Med. 90:427-433							
	211 4-1 1994 AIDS	5, 8: 1695-1699							
	DO Gill et al., 1994, 1112	Eng. J. Med. 335:1261-1269							
	DP Gill et al., 1996, New	D. J. Haamatol 45:221-223							
	DQ Goldman et al., 1980	Br. J. Haematol. 45:221-223							
	DR Guyader et al., 1987,	Nature 326:662-669	269-280						
	Hammarskiold and F	Rekosh, 1989, Biochem. Biophys. Acta 989:2	207-200						
	1005 Lancet	346:118-119							
	DT Harris, 1995, Lancet	S Res. Hum. Retroviruses S:96							
	DU Hermans, 1995, All	OS Res. Hum. Retroviruses S:96							
	DV Hermans et al., 199	5, Cell. Mol. Biol. 3:357-364							
	DW Hershko et al., 1979	9, Lancet 1:945-947							
	DX Heymsfield et al., A	Am. J. Clin. Nutr. 36:Oct. 1982, p. 680-690	304						
	Hirokawa et al. 19	82, Clin. Immunol. Immunopation							
	Terstar	open, 1992, Nature 300.743-747							
	Liscon et al	DZ Huang and Terstappen, EA Hutchinson et al., 1978, J. Biol. Chem. 253:6551-6560							
	EA Hutchinson et al.,	nt. J. Pepetide Protein Res. 39:137-144							
	EB Iyer et al. 1992, II	5, Br. J. Haematol. 61:739-745							
1	EC Juttner et al., 1983	Med 112:254-261							
-	EC Juttier et al., 1990, am. Ann. Med. 112:254-261 ED Kahn et al., 1990, am. Ann. Med. 112:254-261								
	EE Kardana et al., B	J. Cancer 1993 67:686-692							
	Vatz et al., 1985.	Leukemia Res. 9:191-198							
	Katz et al., 1986	, Leukemia Res. 10:961-971							
	at all 10	984, Blood 64:1159-1162							
		2 2 248.1109-1112							
	EH Keating et al., EI Kestler et al., 990, Science 248:1109-1112 EJ Keutmann et al., 1987, Proc. Natl. Acad. Sci. USA 84:2038-2042 EJ Keutmann et al., 1987, Proc. Natl. Acad. Sci. USA 84:2038-2042								
	EJ Keutmann et al.	, 1907, 1100. 1907, 1907							
	EK Keutmann et al	., 1988, Biochemistry 27:8939-8944							
	EL Klatzmann et a	1., 1984, Nature 312:767-768							
1		Continue on Page 6	DATE CONSIDERED						
EXA	MINER	As aitation is in conform	ance with MPEP § 609; Draw line through h next communication to the applicant.						
	MINER: Initial if citation cons	idered, whether or not citation is in conformation of considered. Include copy of this form with	h next communication to the approximation						





ATTORNEY DOCKET NO. 4115-116 DIV 4

SERIAL NO. 09/677,152

INFORMATION DISCLOSURE STATEMENT

(use several sheets if necessary)

APPLICANT Gallo et al. GROUP FILING DATE October 2, 2000

(use	e severai	
		THER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)
		THER DOCUMENTS (Including Author, Title, Journal Bus)
XAMINER		1004 J. Clin. Invest 73:1377-1384
NITIAL	EM	Kodo et al., 1984, J. Clin. Invest. 73:1377-1384
-/-	EN	Kodo et al., 1964, 3. Gan. Kopp et al., 1993, AIDS Res. Hum. Retroviruses 9:267-275
	1=0+	Korbling et al., 1986, Blood 67:529-532
	EO	Kornyei et al., 1993, Biol. Reprod. 49:1149-1157
	EP	Krown et al., 1990, Ann. Intern. Med. 112:812-821
	EQ	Krown et al., 1990, Ann. Intern. 22
	ER	Lajtha, 1979, Differentiation 14:23-34
	ES	Lajtha, 1979, Blood Cells 5:447-455
		Laphorn et al., 1994, Nature 369:455-461
	ET	Leary et al., 1987, Blood 69:953-956
	EU	Leary et al., 1987, Blood 5
-	EV	Letvin et al., 1990, J. AIDS 3;1023-1040
-	- EW	Longhi et al., 1986, J. Immunol. Meth. 92:89-95 Longhi et al., 1986, J. Immunol. Meth. 92:89-95
-	-EX	Lord and Spooncer, 1986, Lymphokine Res. 3.3772
	EY	Louache et al., 1992, Blood 180:2991-2999
	EZ	1 1092 Blood 61:250-256
		11 Learder et al. 1989, J. Clin. Invest. 85.010 91
	FA	Lemardi-Iskandar at al., 1989, Leukemia Res. 15.575
	FE	1: Iskandar at al., 1995, Nature 3/3.04-00
	FC	D Maddon et al., 1986, Cell 47:333-348 D Maddon et al., 1986, Cell 47:333-348
	F	Designed Chemical Endocrinology (App.
	F	E Martin, 1991, Basic and Chemes F Masood et al., 1984, AIDS Res. Hum. Retroviruses 10:969-976
-	F	F Masood et al., 1984, AIDS Res. 114
	F	F Masood et al., 1986, Science, 231:382-385 FG McDougal et al., 1986, Science, 231:382-385
	 ;	FG McDougar et al., 1969, FH Merrifield, 1963, J. Amer. Chem. Soc. 85:2149-2156
		Mitsuva et al., 1991, Science 249:1533-1544
	\	Moore et al., 1980, Blood 55:682-690
	1	1988, Science 242:426-430
		Nicola et al. 1980, J. Cell. Physiol. 103:217-237
		Continue on rugs = L DATE CONSIDERED
		11/25/02

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP \$ 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.





ATTORNEY DOCKET NO. 4115-116 DIV 4

SERIAL NO. 09/677,152


APPLICANT Gallo et al.

INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)

FILING DATE October 2, 2000 GROUP

(us	e severar	October 2, 2000
		Number Etc.)
		THER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)
· · · · · · · · · · · · · · · · · · ·	FM	Nicola et al., 1981, Blood 58:376-386
AMINER.	FIVI	Nijhof et al., 1983, J. Cell. Biol. 96:386-392
77,	FN	Nijhof et al., 1965, 5. Cell. 235.
	FO	Nijhof et al., 1984, Exp. Cell. Res. 155:583-587
	FP	Nothdurft et al., 1977, Scand. J. Haematol. 19:470-481
		Ochs et al., 1981, Pediatr. Res. 15:601
	FQ	Paige et al., 1981, J. Exp. Med. 153:154-165
	FR	
	FS	Paul, 1994, Cell 82:177-182
	FT	Perelson et al., 1966, Science 15:1582-1586
		Pierce et al, 1991, Rev. Biochem., 50:465-495
	FU	Pierce et al, 1991; 1891
	FV	Pillow et at., 1966, New Eng. J. Med. 275:94-97
	FW	Popescu et al., 1995, JNCI 88:450-454
	FX	Popovic et al., 1984, Science 224:497-500
		Prummer et al., 1985, Exp. Hematol. 13:891-898
	FY	Prummer et al., 1903, Endocrinology 126:687-694 Puisieux et al., 1990, Endocrinology 126:687-694
	FZ	Puisieux et al., 1990, Endocrinorgy Raghavacher et al., 1983, J. Cell. Biochem. Suppl. 7A:78
	GA	Raghavacher et al., 1963, J. Coll. 2001.
	GB	Reiffers et al., 1986, Exp. Hematol. 14:312-315
	GC	Reiners et al., 1978, Proc. Natl. Acad. Sci. USA 75:2933-2936 Reisner et al., 1978, Proc. Natl. Acad. Sci. USA 75:2933-2936
	GD	Reisner et al., 1982, Blood 59:360-363
	GE	0.1022.1020
		1 1004 Prenatal Diagnosis (Royal College of Obstett Icians and System
	GF	1 1000 EASER 1 2:2661-2669
	GC	Ryan et al., 1966, 1 ASES v. 2.
	Gl	H Salahuddin et al., 1988, Science 242:430-433
	GI	Sarpel et al., 1979, Exp. Hematol. 7:113-120
-	G.	J Schall, 1991, Cytokine 3:165-183
	- $+$ G	K Schooley et al., 1990, ann. Int. Med. 112:247-253
		L Sherman, 1992, J. Mol. Endocrinol. 6:951-959
		5: 1 4-1 1000 Cancer 65:492-498
4		Continue on Page 8
		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.





ATTORNEY DOCKET NO. US Dept. of Commerce 4115-116 DIV 4 Patent and Trademark Office

SERIAL NO. 09/677,152


APPLICANT Gallo et al.

INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)

GROUP FILING DATE

FORMATI	ON DISC	-basta if necessary)	FILING DATE		
(us	e several s	sheets if necessary)	October 2, 200	o Journal-Date, Page Ni	umber, Etc.)
	01	THER DOCUMENTS	Including Author, 11th	e, Journal-Date, Page Ni	
EXAMINER	1				
INITIAL	CN	Smith et al., 1987, Scien	ice 238:1704-1707		
Ss	GN	J. J. Droymeyer	1986, Br. J. Haematol. 63	3:29-34	
1	GO	Smith and Broxineyer,			
	GP	Stevens et al., 1986, Im	munoi. Lett. 12.77		
	GQ	Strauss et al., 1986, Ex	p. Hematol. 14:878-886		
	GR	Strauss et al., 1986, Ex	p. Hematol. 14:935-945		
		Strauss et al. 1992	, Leukemia 6:993-1000		
	GS	Terstappen et al., 1992			
	GT	Thomas et al., 1972, L	ancer 1 (745)		
	GU	Tilly et al., 1986, Land	cet, July 19 pp. 154-155	200	
-	GV	To and Juttner, 1987,	Br. J. Haematol. 66:285-	-288	
		Towns et al. 1987. In	nmunol. Inv. 16:607-618		
	GW	Touraine, 1983, Birth	Defects 19:139-142		
	GX	Touraine, 1983, Birti	Defects 13.1	3	
	GY	Triozzi et al., 1994, I	nt. J. Oncol. 5:1447-145	SA 72:4100-4104	
-	GZ	Tulunay et al., 1975,	Proc. Natl. Acad. Sci US	SA 72.4100	
1	HA	1073 Am	Obstet. Gynecol. 113.6	101-000	
	HB	Van Gemen et al., 19	994, J. virol. Methods 49	7.137 100	
1	HC HC	1 1000	Science 24(): 142/-1437		
	HD	Vaslin et al., 1994,	AIDS Res. Hum. Retrov	iruses 10.12 11 12	
		Vickery et al., 1983	, J. Parasitol. 69:478-48.	J	
	HE	Victory et al. 1984	J. Exp. Med. 59:1576-15	590	New York) np. 25-80
	HF	1 1 1 1 1001	Reproduction in Domest	IC Ammais (Means)	ess, New York) pp. 25-80
	HC	1.0	os infactions Agents an	d discuse	
	HI	H Weinroth et al., 19	1002 Proc Natl Aca	d. Sci. USA 79:3608-361	2
	H	I Whitlock and Witt	e, 1982, Floc. Hatt. 7100	13-250	
-	H	J Williams et al., 19	987, Exp. Hematol. 15:24	Sci. USA 7414012-4016	
	 	K Winchester et al.,	1977, Proc. Natl. Acad.	Sci. USA 7414012-4016	
		1002 I Mol	Endocrinol., June 10:3.	3/-3 4 3	
		M Yarchoan et al., 1	989, Proc. Vth Int. Conf	. On AIDS, p.304	
	1	DI Vunis 1983. Sci	ence 221:227-236		DATE CONSIDERED
	1	HN Yunis, 1983, 3cm			11/25/02
ENA	MINER				== 0 doo. How line through

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.







ATTORNEY DOCKET NO. 4115-116 DIV 4

SERIAL NO. 09/677,152

INFORMATION DISCLOSURE STATEMENT

APPLICANT Gallo et al. GROUP October 2, 2000

& IKAD	NI DICA	CLOSURE STATEMENT	•	DI DIC DATE		GROUP	
IFORMATIC	JN DIS	sheets if necessary)		FILING DATE October 2, 2000		mbor Etc.)	
(use	Severai			ding Author, Title, Journal-Dat	te, Page N	umber, Etc.)	
	0	THER DOCUMENTS (I	incli	October 2, 2000 Iding Author, Title, Journal-Date			
EXAMINER							
INITIAL	НО	Kotler et al., Am. J. Clin.	Nu	tr. 1985 42. 1235 65			
10	110	Watter and Grunfeld, AIE	OS V	Wasting Syndrome, 229-275			
7/1	HP	Kotter and Grunder,	Nh	otr. 1989; 50: 444-447			
V	HQ	Kotler and Grand Kotler et al., Am. J. Clin	. INU	Inst 87(13) 974-981			
	HR	Lunardi-Iskandar et al.,	J. N	atl. Cancer Inst 8/(13)			
		Mastrangelo et al., Sem.	. On	col 1996 23 (1): 4-21			
	HS	Mastrangelo et al., sens	100	2369-2381			
	HT	Mitsuya et al., FASEB	199	1, 2307 22			
	HU	Ott et al., Am J Clin Nu	utr 1	993; 57:15-19			
		Policastro et al., J Biol	Che	em 258: 11492-11499			
	HV	Russo and Russo, Cano	cerl	etters 1995 90: 81-89			
-	HW	Russo and Russo, Cand					
/							
	17	(As)	1	1/25/02			
			/	/			
-							

E voto							Sheet <u>10</u> o	f 10
ORM PTO		US Dept. of Cor Patent and Trad	emark Office	ATTORNEY DOCKET NO. SERIAL NO 09/677,152				
CODMATI	ON DI	SCLOSURE STA al sheets if necess	TEMENT	APPLICANT Gallo et FILING DATE October 2, 2000	LING DATE GROUP			
U.S. PATENT DOCUMENTS NAME CLASS						SUBCLASS	FILING DA	ATE RIATE
EXAMINER INITIAL	НХ	PATENT NUMBER 5,455,968	ISSUE DATE Aug. 29, 1995	Blithe et al.	436	510		
J								
			FOR	EIGN PATENT DOCU	MENTS		TRANSL	ATION
		DOCUMENT NUMBER	PUBLICATIO DATE	COUNTRY	CLA	SS SUBCLASS	1	NO
	H	y 0 211 411 A2	25 Feb 1987	Lurope				

0 211 411 A2 23 Oct 1992 Japan 04300896 HZ PCT 18 Jun 1987 WO87/03487 1A

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Mastrangelo et al., 1996, "Gene therapy for human cancer; an essay for clinicians", Sem. Oncology 23:4-21 Policastro et al., 1983, "The β subunit of human chorionic gonadotropin is encoded by multiple genes", J. ΙB Riddell et al., 1996, "T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in IC HIV-infected patients", Nat. Med. 2:216-222 ID Continue on Page ___

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.